SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
ALXO reported Third Quarter 2026 results. The price and volatility reaction is pending.
ALXOearnings

Earnings reactions, page 2

ALX Oncology Holdings Inc. (ALXO) Q3 FY2026 earnings

November 16, 2026 · SharpeIQ Research Desk

Reported results

  • Cash, cash equivalents and investments as of September 30, 2026, were $147.2 million.
  • GAAP R&D expenses for the three months ended September 30, 2026 were $17.5 million.
  • GAAP G&A expenses for the three months ended September 30, 2026 were $5.5 million.
  • GAAP net loss was ($21.8) million, or ($0.15) per basic and diluted share, for the three months ended September 30, 2026.
  • Non-GAAP net loss was ($18.9) million for the three months ended September 30, 2026.

Guidance

  • The Company believes its cash, cash equivalents and investments are sufficient to fund planned operations through the first half of 2028.

Price and volatility reaction

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-16 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →